BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

SCYNEXIS, Inc. 

P.O. Box 12878

Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-544-8600 Fax: 919-544-8697


SEARCH JOBS




Industry
Biotechnology


Collaborations

Merck & Co., Inc.  Antifungals





 Company News
SCYNEXIS, Inc. Announces Launch Of Initial Public Offering Of Common Stock 3/24/2014 9:44:57 AM    More...
Durham's SCYNEXIS, Inc. Files For $55 Million IPO 3/3/2014 7:47:31 AM    More...
SCYNEXIS, Inc. Appoints Carole Sable, MD, As Chief Medical Officer 2/24/2014 6:44:30 AM    More...
SCYNEXIS, Inc. Receives Qualified Infectious Disease Product (QIDP) Designation From The FDA For Antifungal Agent SCY-078 For Oral Use 2/21/2014 9:05:24 AM    More...
SCYNEXIS, Inc. Appoints Vivian Doelling As Vice President Of Animal Health 11/20/2013 11:31:34 AM    More...
SCYNEXIS, Inc. Gains Worldwide Rights to Novel Antifungal Compound 5/30/2013 11:06:56 AM    More...
SCYNEXIS, Inc. Presents SCY-635 Data on HCV at International Liver Congress 4/25/2013 10:21:03 AM    More...
SCYNEXIS, Inc. and Immune Design Corporation Collaborate on Innovative Process for Vaccine Production Technology 4/10/2013 11:33:17 AM    More...
SCYNEXIS, Inc.'s Oral SCY-635 Shows Potential as an Immune Acting Antiviral to Augment Current HCV Treatments 11/12/2012 9:31:23 AM    More...
SCYNEXIS, Inc. to Report Phase 2a Study of SCY-635 for Treatment of HCV at American Association for Study of Liver Diseases 11/5/2012 9:17:07 AM    More...
123456